<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299182</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0146</org_study_id>
    <nct_id>NCT00299182</nct_id>
  </id_info>
  <brief_title>Study of AMG 531 to Evaluate the Safety &amp; Efficacy in Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of AMG 531 that can
      be given to treat thrombocytopenia (low platelet counts) in patients who have received
      chemotherapy. Researchers will also look at the safety and effectiveness of AMG 531.

      Primary Objectives:

        1. To determine the clinical safety and tolerability of AMG 531 administered following
           chemotherapy (R-HyperCVAD alternating with R-Ara-C/MTX) in patients with non-Hodgkin's
           lymphoma.

        2. To determine an optimal biologic dose (OBD) of AMG 531 in patients receiving R-HyperCVAD
           and R-Ara-C/MTX.

        3. To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and
           platelet recovery following chemotherapy(chemo).

      Secondary Objectives:

      1. To evaluate limited pharmacokinetics of AMG 531 administered by S.C. route with
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelets are cells that help make the blood clot. A decrease in platelets can cause
      bleeding, which may prevent or delay a patient from receiving chemotherapy. R-HyperCVAD
      (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and R-Ara-C/MTX
      (rituximab, cytarabine, and methotrexate) are two chemotherapy regimens that are known to
      increase the risk of lower platelet counts. Researchers want to find out if AMG 531 can lower
      the risk and severity of this side effect. AMG 531 is a protein that stimulates platelet
      production.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a complete medical history and physical exam, including measurement of
      vital signs (temperature, pulse, breathing rate, and blood pressure). You will have blood
      collected (about 3 teaspoons) for routine tests. Radiologic tests such as CT or MRI scans
      will be done as needed. Women who are able to have children must have a negative blood
      pregnancy test.

      You will also have about 1 teaspoon of blood drawn to see if the you have antibodies to the
      study drug.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of four treatment groups. These 4 groups will also be split
      into 2 separate subgroups (Arm A and Arm B). Participants in Arm A will either receive AMG
      531 or placebo on Day -5 (5 days before chemotherapy starts) and Day 5 (5 days after
      chemotherapy starts). A placebo is a substance that looks like the study drug but which has
      no active ingredients. Every 2 out of 3 participants in Arm A will receive AMG 531. One out
      of every 3 participants in Arm A will receive placebo.

      Participants in Arm B will receive either AMG 531 or placebo on Day 5 and 7. Every 2 out of 3
      participants in Arm B will receive AMG 531. One out of every 3 participants in Arm B will
      receive placebo. The dose of AMG 531 that participants in both Arms A and B receive will
      depend on when they enroll on the study. There are 3 different dose levels of AMG 531 being
      studied. Each new group of participants will receive a higher dose than the previous group.

      All participants will receive treatment with R-HyperCVAD and R-Ara-C/MTX chemotherapy by vein
      in alternating cycles. In Cycle 1, all participants will receive R-HyperCVAD by itself. Each
      cycle is 3 weeks long.

      Three (3) weeks later, in Cycle 2, all participants will receive either AMG 531 or placebo
      following R-Ara-C/MTX. The AMG 531/placebo will be given as an injection under the skin on
      Days -5 and 5 (Arm A) or on Days 5 and 7 (Arm B). After 2 cycles of treatment, based on
      response of the disease and tolerance to the treatment, all participants may be able to
      receive up to 4 more cycles of chemotherapy followed by AMG 531. For Cycles 3-6, you will
      follow the same schedule of therapy as in the first 2 cycles. The dose of AMG 531 may be
      increased at one time point during the study based on the response of the platelet counts.

      Blood (about 1 teaspoon) will be collected for the evaluation of anti-AMG 531 antibody status
      at the end of Cycles 2 and 4. You will be taken off the study if your disease gets worse or
      intolerable side effects occur. The number of blood tests drawn will depend on your clinical
      condition. These samples (about 1 teaspoon each) will be taken at least 2 times a week and as
      often as once a day during anticipated periods of low blood cell counts.

      At the end of the study, you will have an interim medical history and physical exam,
      including measurement of vital signs. You will have blood (about 1 teaspoon) drawn for
      routine end-of-study analysis. Blood (about 1 teaspoon) will also be collected for the
      evaluation of anti-AMG 531 antibody status.

      This is an investigational study. R-HyperCVAD and R-Ara-C/MTX are commercially available
      chemotherapy drugs. AMG 531 is not FDA approved or commercially available. At this time, AMG
      531 is being used in this study for research purposes only. About 36 evaluable patients
      (maximum of 50 patients) will take part in this study. All will be enrolled at University of
      Texas (UT) M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal biologic dose (OBD) of AMG 531 given to treat thrombocytopenia (low platelet counts) in participants who have received chemotherapy</measure>
    <time_frame>Continual reassessment method with each 3 week cycle, up to 6 cycles.</time_frame>
    <description>Optimal biologic dose (OBD) of AMG 531 in participants receiving chemotherapy (R-HyperCVAD and R-Ara-C/MTX) where dose levels are escalated if &lt;/= 1 of the 6 participants enrolled experience dose-limiting toxicity (DLT, as defined by Grade 3 non-hematologic, major organ toxicity) related to AMG 531 at that dose level in a 3 week period. If &gt;/= 2 out of 6 participants in any cohort experience DLT related to AMG 531, no further dose-escalation takes place and the OBD is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Toxicity assessments with each dose level/cycle (3 week cycle) up to 6 cycles</time_frame>
    <description>Number of participants experiencing an adverse event (AE) or serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles on the study.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy
Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (R-HyperCVAD) alone.
Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 531</intervention_name>
    <description>Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>Romiplostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, &amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>AD</other_name>
    <other_name>Hydroxydaunomycin hydrocholoride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,&amp; 5.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 &amp; 6.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 &amp; 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 &amp; 4 for patients &gt; 60 years and for patients with serum creatinine &gt; 1.5 mg/dL; Cycles 2,4,&amp; 6.</description>
    <arm_group_label>1 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Pre &amp; Post Chemotherapy</arm_group_label>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
    <arm_group_label>1 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/ kg AMG531 Post Chemotherapy</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.</description>
    <arm_group_label>Placebo (Arm A &amp; Arm B) with Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of previously untreated aggressive non-Hodgkin's lymphoma,
             including patients with mantle cell lymphoma, who will be or are receiving treatment
             with R-HyperCVAD and R-Ara-C/MTX. Patients in whom Rituximab is not used, due to
             contraindication, will be eligible. Patients whose therapy was switched to
             (R)Hyper-CVAD after initial treatment with (R)CHOP, because of aggressive disease will
             also be eligible for the study.

          2. Patients age &gt;/= 18 years.

          3. Karnofsky Performance Scale &gt;/= 70.

          4. Adequate hematologic (ANC &gt;/= 1000/mm(3), platelet count &gt;/= 100,000/mm(3) and Hgb &gt;/=
             8gm/dL), renal (serum creatinine &lt; 2mg/dL), and hepatic functions (total bilirubin &lt;/=
             2 times, serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate
             transaminase (SGOT) &lt;/= 3 times the upper limit of the respective normal range).

          5. Patients (male and female) with childbearing potential (defined as not post-menopausal
             for 12 months or no previous surgical sterilization) must use adequate birth control.

          6. Institutional Review Board (IRB)-approved signed informed consent.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. History of Central Nervous System (CNS) involvement.

          3. Co-morbid medical or psychiatric illnesses that preclude treatment with intense dose
             chemotherapy.

          4. Patients with history of deep vein thrombosis (DVT) or pulmonary embolus.

          5. History of any platelet disorders including Idiopathic thrombocytopenic purpura (ITP),
             Thrombotic thrombocytopenic purpura (TTP) or bleeding disorders.

          6. Prior surgery or Radiation Therapy (RT) within 2 weeks of study entry.

          7. Patients with significant cardiac disease (New York Heart Association (NYHA) Class III
             or IV), dysrrhythmia, or recent history of myocardial ischemia (MI) or ischemia,
             transient ischemic attack or cerebrovascular accident (CVA) within the previous 6
             months of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>AMG 531</keyword>
  <keyword>Romiplostim</keyword>
  <keyword>Placebo</keyword>
  <keyword>R-HyperCVAD</keyword>
  <keyword>R-Ara-C/MTX</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Decadron</keyword>
  <keyword>Neosar</keyword>
  <keyword>AD</keyword>
  <keyword>Hydroxydaunomycin hydrocholoride</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 4, 2016</submitted>
    <returned>September 30, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

